Measles cases ‐ convalescent serum · susceptible people exposed to measles
Immunoglobulin probably leads to lower measles cases ‐ convalescent serum compared with no treatment (moderate certainty).
1 finding from 1 review
Measles cases ‐ adult serum · susceptible people exposed to measles
Immunoglobulin probably leads to lower measles cases ‐ adult serum compared with no treatment (moderate certainty).
1 finding from 1 review
Measles cases ‐ gamma globulin · susceptible people exposed to measles
Immunoglobulin probably leads to lower measles cases ‐ gamma globulin compared with no treatment (moderate certainty).
1 finding from 1 review
Mortality due to measles · susceptible people exposed to measles
Immunoglobulin leads to lower mortality due to measles compared with no treatment (high certainty).
1 finding from 1 review
Complications due to measles · susceptible people exposed to measles
Immunoglobulin probably leads to lower complications due to measles compared with no treatment (moderate certainty).
1 finding from 1 review
Adverse events · susceptible people exposed to measles
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score on Rankin scale · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found